Details of Drug-Metabolizing Enzyme (DME)

General Information of Drug-Metabolizing Enzyme (DME) (ID: DE43MW5)

DME Name Indoleamine 2,3-dioxygenase 1 (IDO1)
Synonyms Indoleamine-pyrrole 2,3-dioxygenase; IDO; IDO-1; IDO1; INDO
Gene Name IDO1
UniProt ID
I23O1_HUMAN
INTEDE ID
DME0171
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Gene ID
3620
EC Number EC: 1.13.11.52
Oxidoreductase
Oxygen single donor oxidoreductase
Oxygen single donor oxidoreductase
EC: 1.13.11.52
Lineage Species: Homo sapiens
Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens
Sequence
MAHAMENSWTISKEYHIDEEVGFALPNPQENLPDFYNDWMFIAKHLPDLIESGQLRERVE
KLNMLSIDHLTDHKSQRLARLVLGCITMAYVWGKGHGDVRKVLPRNIAVPYCQLSKKLEL
PPILVYADCVLANWKKKDPNKPLTYENMDVLFSFRDGDCSKGFFLVSLLVEIAAASAIKV
IPTVFKAMQMQERDTLLKALLEIASCLEKALQVFHQIHDHVNPKAFFSVLRIYLSGWKGN
PQLSDGLVYEGFWEDPKEFAGGSAGQSSVFQCFDVLLGIQQTAGGGHAAQFLQDMRRYMP
PAHRNFLCSLESNPSVREFVLSKGDAGLREAYDACVKALVSLRSYHLQIVTKYILIPASQ
QPKENKTSEDPSKLEAKGTGGTDLMNFLKTVRSTTEKSLLKEG
Function This enzyme catalyzes the first and rate limiting step of the catabolism of the essential amino acid tryptophan along the kynurenine pathway.
KEGG Pathway
African trypanosomiasis (hsa05143 )
Metabolic pathways (hsa01100 )
Tryptophan metabolism (hsa00380 )
Reactome Pathway
Tryptophan catabolism (R-HSA-71240 )

Molecular Interaction Atlas (MIA) of This DME

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DME
2 Approved Drug(s) Metabolized by This DME
Drug Name Drug ID Indication ICD 11 Highest Status REF
L-Tryptophan DMIBH7M Depression 6A70-6A7Z Approved [23]
Melatonin DMKWFBT Depression 6A70-6A7Z Approved [24]
Experimental Enzyme Kinetic Data of Drugs
Drug Name Indication Highest Status Kinetic Data REF
L-Tryptophan Depression [6A70-6A7Z] Approved Km = 0.0141 microM [25]

Molecular Expression Atlas (MEA) of This DME

Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This DME
Disease Name ICD 11 Studied Tissue p-value Fold-Change Z-score
Acute myelocytic leukaemia 2B33.1 Bone marrow 8.55E-03 -4.30E-02 -1.43E-01
Alopecia ED70 Skin from scalp 2.99E-07 3.84E-01 1.01E+00
Alzheimer's disease 8A20 Entorhinal cortex 1.46E-02 -4.58E-02 -2.16E-01
Ankylosing spondylitis FA92.0 Pheripheral blood 1.22E-01 -8.18E-02 -7.60E-02
Aortic stenosis BB70 Calcified aortic valve 1.29E-02 5.26E-01 1.06E+00
Apnea 7A40 Hyperplastic tonsil 1.61E-01 3.80E-01 1.04E+00
Arthropathy FA00-FA5Z Peripheral blood 1.54E-01 2.06E-01 3.07E-01
Asthma CA23 Nasal and bronchial airway 8.04E-04 1.35E+00 6.61E-01
Atopic dermatitis EA80 Skin 1.47E-04 2.04E-01 9.74E-01
Autism 6A02 Whole blood 5.61E-01 -1.17E-01 -1.59E-01
Autoimmune uveitis 9A96 Peripheral monocyte 3.86E-01 8.04E-02 5.05E-01
Autosomal dominant monocytopenia 4B04 Whole blood 1.62E-01 -1.30E+00 -7.87E-01
Bacterial infection of gingival 1C1H Gingival tissue 1.80E-03 2.60E-01 3.87E-01
Batten disease 5C56.1 Whole blood 1.24E-01 -1.67E-01 -1.08E+00
Behcet's disease 4A62 Peripheral blood 8.66E-02 1.98E-01 6.63E-01
Bipolar disorder 6A60-6A6Z Prefrontal cortex 9.87E-01 -6.29E-02 -3.20E-01
Bladder cancer 2C94 Bladder tissue 5.59E-03 1.28E-01 3.47E-01
Breast cancer 2C60-2C6Z Breast tissue 1.11E-14 4.23E-01 4.40E-01
Cardioembolic stroke 8B11.20 Whole blood 2.18E-05 -1.03E+00 -1.41E+00
Cervical cancer 2C77 Cervical tissue 4.38E-06 9.08E-01 1.27E+00
Childhood onset rheumatic disease FA20.Z Peripheral blood 7.87E-01 -7.01E-01 -3.71E-01
Chronic hepatitis C 1E51.1 Whole blood 8.23E-01 5.83E-02 3.10E-01
Chronic obstructive pulmonary disease CA22 Lung tissue 9.00E-02 2.22E-01 2.77E-01
Chronic obstructive pulmonary disease CA22 Small airway epithelium 2.64E-01 -1.10E-01 -7.20E-02
Chronic rhinosinusitis CA0A Sinus mucosa tissue 1.14E-01 7.43E-01 3.42E+00
Colon cancer 2B90 Colon tissue 1.29E-17 3.95E-01 5.50E-01
Coronary artery disease BA80-BA8Z Peripheral blood 1.56E-01 -4.85E-01 -1.20E+00
Diffuse large B-cell lymphoma 2A81 Tonsil tissue 1.03E-01 -4.14E-01 -1.28E+00
Endometriosis GA10 Endometrium tissue 1.37E-01 1.88E-01 1.09E-01
Familial hypercholesterolemia 5C80.00 Peripheral blood 4.81E-01 -2.33E-02 -7.29E-02
Familial hypercholesterolemia 5C80.00 Whole blood 7.73E-04 -4.98E-01 -1.07E+00
Gastric cancer 2B72 Gastric tissue 4.13E-01 2.56E+00 1.01E+00
Glioblastopma 2A00.00 Nervous tissue 4.82E-39 3.62E-01 9.90E-01
Glioma 2A00.0Y-2A00.0Z Brain stem tissue 8.09E-01 -1.10E-01 -3.73E-01
Glioma 2A00.0Y-2A00.0Z White matter tissue 2.05E-02 2.10E+00 1.16E+00
Head and neck cancer 2D42 Head and neck tissue 2.64E-07 1.75E+00 9.59E-01
HIV-associated neurocognitive impairment 8A2Y-8A2Z White matter tissue 2.90E-01 -2.80E-02 -8.32E-02
Huntington's disease 8A01.10 Whole blood 5.33E-01 1.05E-01 1.25E-01
Idiopathic pulmonary fibrosis CB03.4 Lung tissue 1.64E-01 9.74E-01 1.32E+00
Immunodeficiency 4A00-4A20 Peripheral blood 6.52E-02 1.35E-01 1.78E+00
Influenza 1E30 Whole blood 7.17E-01 -4.28E-02 -1.03E-01
Interstitial cystitis GC00.3 Bladder tissue 2.27E-03 2.28E+00 6.18E+00
Intracranial aneurysm 8B01.0 Intracranial artery 1.31E-02 3.50E-01 9.32E-01
Irritable bowel syndrome DD91.0 Rectal colon tissue 9.77E-01 5.80E-02 7.95E-02
Ischemic stroke 8B11 Peripheral blood 6.95E-01 3.17E-02 1.04E-01
Juvenile idiopathic arthritis FA24 Peripheral blood 7.63E-05 -3.63E-01 -2.63E-01
Lateral sclerosis 8B60.4 Skin 1.78E-01 1.02E-01 4.70E-01
Lateral sclerosis 8B60.4 Cervical spinal cord 8.15E-02 1.42E-01 7.53E-01
Liver cancer 2C12.0 Liver tissue 6.99E-08 2.94E-01 8.36E-01
Liver failure DB99.7-DB99.8 Liver tissue 2.96E-04 5.83E-01 3.69E+00
Lung cancer 2C25 Lung tissue 1.34E-05 -5.52E-01 -4.99E-01
Lupus erythematosus 4A40 Whole blood 3.13E-02 -2.59E-01 -1.62E-01
Major depressive disorder 6A70-6A7Z Hippocampus 2.11E-01 6.71E-02 3.49E-01
Major depressive disorder 6A70-6A7Z Whole blood 3.47E-01 1.19E-01 1.80E-01
Melanoma 2C30 Skin 9.53E-07 1.13E+00 1.20E+00
Multiple myeloma 2A83.1 Peripheral blood 7.10E-01 1.33E-02 5.27E-02
Multiple myeloma 2A83.1 Bone marrow 3.79E-01 -1.26E-01 -7.06E-01
Multiple sclerosis 8A40 Plasmacytoid dendritic cells 4.38E-01 1.92E-01 5.77E-01
Myelodysplastic syndrome 2A36-2A3Z Bone marrow 9.17E-01 -1.04E-03 -3.74E-03
Myelofibrosis 2A20.2 Whole blood 1.97E-03 -6.30E-01 -1.54E+00
Myocardial infarction BA41-BA50 Peripheral blood 2.43E-01 1.84E-01 2.15E-01
Myopathy 8C70.6 Muscle tissue 8.64E-03 1.05E+00 1.80E+00
Neonatal sepsis KA60 Whole blood 3.46E-10 -8.57E-01 -1.28E+00
Neuroectodermal tumour 2A00.11 Brain stem tissue 5.28E-01 -2.31E-01 -4.60E-01
Non-alcoholic fatty liver disease DB92 Liver tissue 8.20E-02 1.19E-01 5.27E-01
Obesity related type 2 diabetes 5A11 Omental adipose tissue 5.53E-01 -1.39E-01 -2.16E-01
Olive pollen allergy CA08.00 Peripheral blood 2.91E-01 -1.48E+00 -6.87E-01
Oral cancer 2B6E Oral tissue 3.48E-27 1.50E+00 3.87E+00
Osteoarthritis FA00-FA0Z Synovial tissue 5.28E-01 -2.36E-01 -3.70E-01
Osteoporosis FB83.1 Bone marrow 4.70E-01 3.25E-01 6.93E-01
Ovarian cancer 2C73 Ovarian tissue 3.69E-06 2.12E+00 3.26E+00
Pancreatic cancer 2C10 Pancreas 8.71E-02 3.88E-01 4.27E-01
Parkinson's disease 8A00.0 Substantia nigra tissue 8.21E-01 -2.09E-02 -5.86E-02
Pediatric respiratory syncytial virus infection CA40.11 Peripheral blood 4.69E-01 -1.90E-03 -7.98E-03
Pituitary cancer 2D12 Pituitary tissue 4.23E-01 2.46E-01 2.10E-01
Pituitary gonadotrope tumour 2D12 Pituitary tissue 5.24E-01 0.00E+00 0.00E+00
Polycystic ovary syndrome 5A80.1 Vastus lateralis muscle 7.44E-02 -1.79E-01 -8.10E-01
Polycythemia vera 2A20.4 Whole blood 4.68E-01 -4.52E-02 -1.04E-01
Pompe disease 5C51.3 Biceps muscle 9.24E-01 -3.77E-01 -4.58E-01
Preterm birth KA21.4Z Myometrium 7.17E-01 2.99E-01 3.11E-01
Prostate cancer 2C82 Prostate 3.75E-01 -1.71E-01 -2.06E-01
Psoriasis EA90 Skin 4.83E-31 7.69E-01 1.94E+00
Rectal cancer 2B92 Rectal colon tissue 9.48E-02 3.63E-01 7.85E-01
Renal cancer 2C90-2C91 Kidney 2.30E-14 1.73E+00 5.68E+00
Retinoblastoma 2D02.2 Uvea 5.31E-02 3.92E-01 6.88E-01
Rheumatoid arthritis FA20 Synovial tissue 9.50E-02 4.06E-01 5.95E-01
Rhinovirus infection CA42.1 Nasal epithelium tissue 8.74E-01 -2.03E-01 -2.28E-01
Schizophrenia 6A20 Prefrontal cortex 2.17E-02 1.78E-01 3.56E-01
Schizophrenia 6A20 Superior temporal cortex 5.34E-02 -1.74E-01 -9.30E-01
Scleroderma 4A42.Z Whole blood 1.87E-02 5.12E-01 1.03E+00
Seizure 8A60-8A6Z Whole blood 2.44E-01 3.76E-01 2.54E-01
Sensitive skin EK0Z Skin 9.18E-01 1.78E-01 2.61E-01
Sepsis with septic shock 1G41 Whole blood 1.32E-09 -5.85E-01 -8.04E-01
Shwachman-Diamond syndrome 3A70.0 Bone marrow 6.01E-02 3.00E-01 9.95E-01
Sickle cell disease 3A51.0-3A51.3 Peripheral blood 1.74E-03 5.12E-01 1.71E+00
Simpson golabi behmel syndrome LD2C Adipose tissue 1.39E-01 1.77E-01 3.28E+00
Sjogren's syndrome 4A43.2 Salivary gland tissue 3.57E-01 -4.87E-02 -1.75E-01
Skin cancer 2C30-2C3Z Skin 6.01E-38 9.50E-01 1.82E+00
Thrombocythemia 3B63 Whole blood 1.53E-02 -1.01E-01 -2.40E-01
Thrombocytopenia 3B64 Whole blood 5.74E-01 1.60E-01 4.14E-01
Thyroid cancer 2D10 Thyroid 1.84E-01 -1.02E-01 -7.15E-02
Tibial muscular dystrophy 8C75 Muscle tissue 6.19E-04 -9.41E-01 -1.59E+00
Tuberous sclerosis complex LD2D.2 Perituberal tissue 3.70E-02 3.68E-01 1.81E+00
Type 2 diabetes 5A11 Liver tissue 5.84E-01 2.37E-01 7.55E-01
Ureter cancer 2C92 Urothelium 2.08E-01 -1.92E-01 -4.86E-01
Uterine cancer 2C78 Endometrium tissue 4.43E-01 3.09E-01 1.69E-01
Vitiligo ED63.0 Skin 4.39E-01 -2.40E-02 -3.42E-02
------------------------------------------------------------------------------------
⏷ Show the Full List of DME Expression Under 107 Diseases

The Drug Therapeutic Target (DTT) Role of This DME

DME DTT Name Indoleamine 2,3-dioxygenase 1 (IDO1) DTT Info
DME DTT Type Successful
1 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
L-Tryptophan DMIBH7M Depression 6A70-6A7Z Approved [1]
11 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Avastin+/-Tarceva DMA86FL Non-small-cell lung cancer 2C25.Y Phase 3 [2]
BMS-986205 DM3MAYQ Melanoma 2C30 Phase 3 [3]
INCB24360 DMIJGT9 Urothelial carcinoma 2C92.0 Phase 3 [4]
NLG8189 DM0798Z Melanoma 2C30 Phase 2/3 [3]
DN1406131 DMQFX8R Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
HTI-1090 DMI4TEC Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
KHK2455 DMLSUQ8 Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
LY3381916 DMONZ1L Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
MK-7162 DMBSXZ1 Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
NLG802 DMP9J5V Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
PF-06840003 DMOX6EJ Glioma 2A00.0 Phase 1 [8]
⏷ Show the Full List of 11 Clinical Trial Drug(s)
82 Patented Agent(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
2,3-diamino-benzo[b]thiophene derivative 1 DMD2KRW N. A. N. A. Patented [9]
2,3-diamino-benzo[b]thiophene derivative 2 DMDYXKT N. A. N. A. Patented [9]
2,3-diamino-benzo[b]thiophene derivative 3 DMR7QKL N. A. N. A. Patented [9]
2,3-diamino-benzo[b]thiophene derivative 4 DMEDFNC N. A. N. A. Patented [9]
2,3-diamino-benzo[b]thiophene derivative 5 DM05WXD N. A. N. A. Patented [9]
2,3-diamino-benzo[b]thiophene derivative 6 DMINE6V N. A. N. A. Patented [9]
2,3-diamino-benzo[b]thiophene derivative 7 DMQVMNJ N. A. N. A. Patented [9]
2,3-diamino-benzo[b]thiophene derivative 8 DM5O8K0 N. A. N. A. Patented [9]
Acyl piperidine derivative 1 DMX9J1C N. A. N. A. Patented [10]
Amide derivative 2 DMBKIR0 N. A. N. A. Patented [10]
Aryl 1,2-diamine derivative 1 DMSDRNQ N. A. N. A. Patented [10]
Aryl sulphoxide imine derivative 1 DMW7HKS N. A. N. A. Patented [10]
Azetidine derivative 5 DMJ9U0E N. A. N. A. Patented [10]
Benzimidazole and imadazopyridine carboximidamide compound 1 DM2G83R N. A. N. A. Patented [10]
Benzimidazole and imadazopyridine carboximidamide compound 2 DMJ2CIY N. A. N. A. Patented [10]
Biphenyl 1,2-diamine derivative 1 DM1VYZ9 N. A. N. A. Patented [10]
Biphenyl derivative 1 DMG4WQB N. A. N. A. Patented [10]
Biphenyl derivative 2 DMJ4TZX N. A. N. A. Patented [10]
Biphenyl derivative 3 DMM3SWV N. A. N. A. Patented [10]
Carbamide derivative 13 DMCAD64 N. A. N. A. Patented [10]
Cyclic hydroxamate derivative 1 DM0K62M N. A. N. A. Patented [10]
Cyclohexyl-ethyl-substituted diaza and triaza-tricyclic compound 1 DMI2T1D N. A. N. A. Patented [10]
Five-membered heteroaromatic compound 1 DMO8UKD N. A. N. A. Patented [10]
Five-membered heteroaromatic compound 2 DM1QH8Z N. A. N. A. Patented [10]
Five-membered heteroaromatic compound 3 DMS0P9E N. A. N. A. Patented [10]
Hexahydro quinoline derivative 1 DM4VNWX N. A. N. A. Patented [10]
Hydoxyamidine derivative 1 DMFIG8C N. A. N. A. Patented [10]
Hydroxy amidine derivative 1 DMBHIL2 N. A. N. A. Patented [10]
Hydroxy amidine derivative 2 DM7SUFJ N. A. N. A. Patented [10]
Imidazo isoindole derivative 1 DM1JXKY N. A. N. A. Patented [10]
Imidazoleisoindoles derivative 1 DM7UMW2 N. A. N. A. Patented [10]
Imidazoleisoindoles derivative 2 DMRJKIQ N. A. N. A. Patented [10]
Imidazo[1,5-a]pyridine derivative 1 DMFIP0D N. A. N. A. Patented [10]
Imidazo[1,5-a]pyridine derivative 2 DMU3PAR N. A. N. A. Patented [10]
Indazole derivative 2 DMV7AX9 N. A. N. A. Patented [10]
Indazole derivative 3 DMVUWLK N. A. N. A. Patented [10]
Indazole derivative 4 DMJ2CRO N. A. N. A. Patented [10]
Monoaryl-1,2-diamine derivative 1 DMCI6YH N. A. N. A. Patented [10]
Monoaryl-1,2-diamine derivative 2 DMXUNZ1 N. A. N. A. Patented [10]
Monoaryl-1,2-diamine derivative 3 DMAXKPC N. A. N. A. Patented [10]
Monoaryl-1,2-diamine derivative 4 DMD8AKH N. A. N. A. Patented [10]
Monofluorine derivative 1 DMJ8YZK N. A. N. A. Patented [10]
PMID27172114-Compound-30 DMBWLSA N. A. N. A. Patented [9]
PMID29473428-Compound-10 DM7EW5U N. A. N. A. Patented [10]
PMID29473428-Compound-11 DM5MXFK N. A. N. A. Patented [10]
PMID29473428-Compound-14 DMCB0D6 N. A. N. A. Patented [10]
PMID29473428-Compound-15 DM571JP N. A. N. A. Patented [10]
PMID29473428-Compound-16 DM21QCE N. A. N. A. Patented [10]
PMID29473428-Compound-17 DMI04GC N. A. N. A. Patented [10]
PMID29473428-Compound-21 DMZGNWO N. A. N. A. Patented [10]
PMID29473428-Compound-22 DMCNSZD N. A. N. A. Patented [10]
PMID29473428-Compound-29 DMBMTUV N. A. N. A. Patented [10]
PMID29473428-Compound-33 DMZA3FL N. A. N. A. Patented [10]
PMID29473428-Compound-34 DM7BRPI N. A. N. A. Patented [10]
PMID29473428-Compound-39 DMKRUPW N. A. N. A. Patented [10]
PMID29473428-Compound-4 DM9KVOD N. A. N. A. Patented [10]
PMID29473428-Compound-41 DM4AOIR N. A. N. A. Patented [10]
PMID29473428-Compound-43 DMQ8EYV N. A. N. A. Patented [10]
PMID29473428-Compound-47 DMCLJ0M N. A. N. A. Patented [10]
PMID29473428-Compound-48 DMAYT2E N. A. N. A. Patented [10]
PMID29473428-Compound-50 DMXUVDH N. A. N. A. Patented [10]
PMID29473428-Compound-52 DMSXKP6 N. A. N. A. Patented [10]
PMID29473428-Compound-53 DMOASLQ N. A. N. A. Patented [10]
PMID29473428-Compound-54 DMKIS26 N. A. N. A. Patented [10]
PMID29473428-Compound-58 DMVP7DL N. A. N. A. Patented [10]
PMID29473428-Compound-59 DMJYUN2 N. A. N. A. Patented [10]
PMID29473428-Compound-6 DMOVPWD N. A. N. A. Patented [10]
PMID29473428-Compound-60 DMRKWPQ N. A. N. A. Patented [10]
PMID29473428-Compound-70 DMMV5KI N. A. N. A. Patented [10]
PMID29473428-Compound-71 DML5G6D N. A. N. A. Patented [10]
PMID29473428-Compound-72 DMJOBUZ N. A. N. A. Patented [10]
PMID29473428-Compound-76 DM8PZ46 N. A. N. A. Patented [10]
PMID29473428-Compound-80 DM8VBU2 N. A. N. A. Patented [10]
Pyridine derivative 1 DMSGF8T N. A. N. A. Patented [10]
Pyridino tricyclic compound 1 DMKQFTY N. A. N. A. Patented [10]
Pyrrolo[1,2-c]pyrazole derivative 1 DM5RCW8 N. A. N. A. Patented [10]
Sulfamic acid ester derivative 1 DMQ0VK9 N. A. N. A. Patented [10]
Sulfamoylamide derivative 1 DMO7ZRW N. A. N. A. Patented [10]
Sulfonamide derivative 6 DMD51AV N. A. N. A. Patented [10]
Sulfonamide derivative 7 DMN5YUK N. A. N. A. Patented [10]
Sulfonamide derivative 8 DMOXIZC N. A. N. A. Patented [10]
Thieno[2,3-c]pyridine derivative 1 DMLUPV1 N. A. N. A. Patented [10]
⏷ Show the Full List of 82 Patented Agent(s)
3 Preclinical Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
1-methyl-L-tryptophan DMT8SFV Solid tumour/cancer 2A00-2F9Z Preclinical [11]
EPL-1410 DM5K17C Solid tumour/cancer 2A00-2F9Z Preclinical [12]
RG70099 DM7JH0K Solid tumour/cancer 2A00-2F9Z Preclinical [12]
68 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
1,2-NAPHTHOQUINONE DMYXELH Discovery agent N.A. Investigative [2]
1,4-Naphthoquinone DMTCMH7 Discovery agent N.A. Investigative [2]
1H-indole-4,7-dione DMNDVMH Discovery agent N.A. Investigative [13]
2,2-dimethyl-2H-benzo[g]chromene-5,10-dione DMQYCFI Discovery agent N.A. Investigative [2]
2,3-dichloro-1,4-naphthoquinone DMPCGSD Discovery agent N.A. Investigative [2]
2,3-dihydrobenzo[d]thiazole-2-thiol DMUW94S Discovery agent N.A. Investigative [14]
2,4-Dichlorobenzenemethanethiol DMR5DYK Discovery agent N.A. Investigative [15]
2-(1H-Imidazol-4-yl)benzene-1,3-diol DM2PZ1B Discovery agent N.A. Investigative [16]
2-(1H-Imidazol-4-yl)phenol DM6MR82 Discovery agent N.A. Investigative [16]
2-Chlorobenzenemethanethiol DMI89RL Discovery agent N.A. Investigative [15]
2-hydroxygarveatin E DM5E1DC Discovery agent N.A. Investigative [17]
2-HYDROXYGARVIN A DMK96BL Discovery agent N.A. Investigative [17]
2-methoxy-1,4-naphthoquinone DMA5Q4T Discovery agent N.A. Investigative [2]
3,4-Dichlorobenzenemethanethiol DMN61Q5 Discovery agent N.A. Investigative [15]
3-(1H-Imidazol-4-yl)benzenethiol DMERZHK Discovery agent N.A. Investigative [16]
3-(4H-Imidazol-4-yl)benzenethiol DMPS1GW Discovery agent N.A. Investigative [16]
4-(1H-1,2,3-triazol-5-yl)pyridine DMFWVJI Discovery agent N.A. Investigative [14]
4-(2-(diethylamino)ethylamino)-1-naphthol DMRQ8T9 Discovery agent N.A. Investigative [14]
4-(2-Hydroxyethoxy)-1-naphthol DM17QG8 Discovery agent N.A. Investigative [14]
4-(Benzylamino)-1-naphthol DMF6S3X Discovery agent N.A. Investigative [14]
4-(Cyclohexylamino)-1-naphthol DMUOQN7 Discovery agent N.A. Investigative [14]
4-(ethylamino)naphthalen-1-ol DM14C9V Discovery agent N.A. Investigative [14]
4-(Isopropylamino)-1-naphthol DMJFSTX Discovery agent N.A. Investigative [14]
4-(methylamino)naphthalen-1-ol DMF3O10 Discovery agent N.A. Investigative [14]
4-(Pent-3-ylamino)-1-naphthol DMHIDY6 Discovery agent N.A. Investigative [14]
4-(propylamino)naphthalen-1-ol DMEAZFJ Discovery agent N.A. Investigative [14]
4-(tert-butylamino)naphthalen-1-ol DMU5A2B Discovery agent N.A. Investigative [14]
4-amino-1,2,5-oxadiazole-3-carboximidamide DMNXSM2 Discovery agent N.A. Investigative [18]
4-aminonaphthalen-1-ol DMIG82P Discovery agent N.A. Investigative [14]
4-Chlorobenzenemethanethiol DMKTSPM Discovery agent N.A. Investigative [15]
4-Fluorobenzenemethanethiol DMS6RHD Discovery agent N.A. Investigative [15]
4-Methoxybenzenemethanethiol DMVFLCM Discovery agent N.A. Investigative [15]
4-methoxynaphthalen-1-amine DMBS61O Discovery agent N.A. Investigative [14]
4-Methylbenzenemethanethiol DM3S2P8 Discovery agent N.A. Investigative [15]
4-Phenylimidazole DM5UNBW Discovery agent N.A. Investigative [16]
4-phenylthiazole-2-thiol DM3B1CE Discovery agent N.A. Investigative [14]
5-(isopropylamino)quinolin-8-ol DM45VRX Discovery agent N.A. Investigative [14]
5-aminoquinolin-8-ol DMIBHP5 Discovery agent N.A. Investigative [14]
5-phenyl-1H-1,2,3-triazole DMWF4HX Discovery agent N.A. Investigative [14]
amg-1 DMUONK5 Discovery agent N.A. Investigative [19]
ANNULIN A DM0RUQ8 Discovery agent N.A. Investigative [17]
ANNULIN B DMDQXJ2 Discovery agent N.A. Investigative [17]
ANNULIN C DMTYQDO Discovery agent N.A. Investigative [17]
BENZENEMETHANETHIOL DMK5QYW Discovery agent N.A. Investigative [15]
BLV-0801 DMGB9PN Solid tumour/cancer 2A00-2F9Z Investigative [20]
Exiguamine A DMMZH3Q Discovery agent N.A. Investigative [13]
EXIGUAMINE B DME1TGM Discovery agent N.A. Investigative [21]
GARVEATIN A DM7GX1S Discovery agent N.A. Investigative [17]
Garveatin C DMXNQ15 Discovery agent N.A. Investigative [17]
Garveatin E DMUFZ18 Discovery agent N.A. Investigative [17]
N-[2-(Indol-3-yl)ethyl]-S-benzyl-dithiocarbamate DMJ8W6F Discovery agent N.A. Investigative [22]
Naphthalene-1,4-diol DMOQ43W Discovery agent N.A. Investigative [14]
PMID24099220C5i DMWOHAE Discovery agent N.A. Investigative [11]
S-(2,4-Dichlorobenzyl)isothiourea hydrobromide DMO1R69 Discovery agent N.A. Investigative [15]
S-(2-Chlorobenzyl)isothiourea hydrochloride DMN62KP Discovery agent N.A. Investigative [15]
S-(3,4-Dichlorobenzyl)isothiourea hydrochloride DMNMCQJ Discovery agent N.A. Investigative [15]
S-(3-Chlorobenzyl)isothiourea hydrochloride DMNG6JB Discovery agent N.A. Investigative [15]
S-(4-Bromobenzyl)isothiourea hydrobromide DM0XDFG Discovery agent N.A. Investigative [15]
S-(4-Chlorobenzyl)isothiourea hydrochloride DMWJE2X Discovery agent N.A. Investigative [15]
S-(4-Cyanobenzyl)isothiourea hydrobromide DMYGULD Discovery agent N.A. Investigative [15]
S-(4-Ethylbenzyl)isothiourea hydrochloride DMNXDWV Discovery agent N.A. Investigative [15]
S-(4-Fluorobenzyl)isothiourea hydrochloride DM10MET Discovery agent N.A. Investigative [15]
S-(4-Methoxybenzyl)isothiourea hydrochloride DM4XWAU Discovery agent N.A. Investigative [15]
S-(4-Methylbenzyl)isothiourea hydrochloride DMAGLI8 Discovery agent N.A. Investigative [15]
S-(4-Nitrobenzyl)isothiourea hydrochloride DMYRBO0 Discovery agent N.A. Investigative [15]
S-Benzyl-brassinin DM2RLXF Discovery agent N.A. Investigative [22]
Seco-exiguamine DMY7IVZ Discovery agent N.A. Investigative [21]
tryptanthrin DMTRYCI Discovery agent N.A. Investigative [11]
⏷ Show the Full List of 68 Investigative Drug(s)

References

1 Interactions between nitric oxide and indoleamine 2,3-dioxygenase. Biochemistry. 2006 Jul 18;45(28):8527-38.
2 Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem. 2008 Mar 27;51(6):1706-18.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Incyte. Product Development Pipeline.
5 ClinicalTrials.gov (NCT03641794) Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers. U.S. National Institutes of Health.
6 Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation. J Enzyme Inhib Med Chem. 2019 Dec;34(1):250-263.
7 ClinicalTrials.gov (NCT03364049) Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002). U.S. National Institutes of Health.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
10 A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.
11 Discovery of tryptanthrin derivatives as potent inhibitors of indoleamine 2,3-dioxygenase with therapeutic activity in Lewis lung cancer (LLC) tumor-bearing mice. J Med Chem. 2013 Nov 14;56(21):8321-31.
12 Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. 2019 May;18(5):379-401.
13 Synthesis of indoleamine 2,3-dioxygenase inhibitory analogues of the sponge alkaloid exiguamine A. J Med Chem. 2008 May 8;51(9):2634-7.
14 Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2010 Feb 11;53(3):1172-89.
15 S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5126-9.
16 Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase. J Med Chem. 2008 Aug 28;51(16):4968-77.
17 Indoleamine 2,3-dioxygenase inhibitors from the Northeastern Pacific Marine Hydroid Garveia annulata. J Nat Prod. 2006 Oct;69(10):1496-9.
18 Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma mo... J Med Chem. 2009 Dec 10;52(23):7364-7.
19 Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors. Biochim Biophys Acta. 2011 Dec;1814(12):1947-54.
20 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2829).
21 Biomimetic synthesis of the IDO inhibitors exiguamine A and B. Nat Chem Biol. 2008 Sep;4(9):535-7.
22 Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2006 Jan 26;49(2):684-92.
23 Kynurenine pathway metabolites and enzymes involved in redox reactions. Neuropharmacology. 2017 Jan;112(Pt B):331-345.
24 Molecular evidence that melatonin is enzymatically oxidized in a different manner than tryptophan: investigations with both indoleamine 2,3-dioxygenase and myeloperoxidase. Biochem J. 2005 May 15;388(Pt 1):205-15.
25 Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors. Biochim Biophys Acta. 2011 Dec;1814(12):1947-54.